A Study to Evaluate CBP-201, Rademikibart, in Adult Patients With Chronic Rhinosinusitis With Nasal Polyps
Stopped Trial was discontinued in 2022 due to COVID-19 pandemic and Ukraine/Russia conflict related enrollment challenges. Discontinuation was not related to safety.
Conditions
- Chronic Rhinosinusitis With Nasal Polyps
Interventions
- DRUG: CBP-201
- DRUG: Placebo
Sponsor
Connect Biopharm LLC